Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
University of California, Los Angeles · University of Colorado Cancer Center · +38 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
618
total citations
- FWCI
- 58.76
- Percentile
- 100%
- References
- 32
Citations per year
Authors
30- SASara A. HurvitzCorresponding
University of California, Los Angeles, University of Colorado Cancer Center, UCLA Jonsson Comprehensive Cancer Center, University of Colorado Denver
- RHRoberto Hegg
Centro de Pesquisas Oncológicas
- WCWei‐Pang Chung
National Cheng Kung University, National Cheng Kung University Hospital
- SISeock‐Ah Im
Seoul National University Hospital
- WJWilliam Jacot
Institut de Recherche en Cancérologie de Montpellier, Inserm, Université de Montpellier
Topics & keywords
Topics
Keywords
- Trastuzumab
- Trastuzumab emtansine
- Medicine
- Oncology
- Metastatic breast cancer
- Breast cancer
- Internal medicine
- Cancer
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- SSanofi
- GSGilead Sciences
- RPRegeneron Pharmaceuticals
- COClovis Oncology
- RHRadius Health
- MTMersana Therapeutics
- BBeiGene
- IIncyte
- SPSyndax Pharmaceuticals
- NNuCana
- RTRelay Therapeutics
- PBPuma Biotechnology
- MMacroGenics
- GTG1 Therapeutics
- SSeagen
- DDaiichi-Sankyo
- EEisai
- PPharmaMar
- PPlexxikon
- GGenentech
- CPChugai Pharmaceutical
- DSDaiichi Sankyo Europe